Cardiovascular and autonomic phenotype of db/db diabetic mice.
The db/db mice serve as a good model for type 2 diabetes characterized by hyperinsulinaemia and progressive hyperglycaemia. There are limited and conflicting data on the cardiovascular changes in this model. The aim of the present study was to characterize the cardiovascular and autonomic phenotype of male db/db mice and evaluate the role of angiotensin II AT(1) receptors. Radiotelemetry was used to monitor 24 h blood pressure (BP) in mice for 8 weeks. Parameters measured were mean arterial pressure (MAP), heart rate (HR) and their variabilities. In 8-week-old db/db mice, the MAP and BP circadian rhythms were not different from age-matched control mice, while HR and locomotor activity were decreased. With ageing, MAP gradually increased in db/db mice, and the 12 h light values did not dip significantly from the 12 h dark periods. In 14-week-old mice, MAP was increased during light (101 +/- 1 versus 117 +/- 2 mmHg, P < 0.01; control versus db/db mice) and dark phases (110 +/- 1.7 versus 121 +/- 3.1 mmHg, P < 0.01; control versus db/db mice). This increase in MAP was associated with a significant increase in plasma angiotensin-converting enzyme activity and angiotensin II levels. Chronic treatment with losartan (10 mg kg(-1) day(-1)) blocked the increase in MAP in db/db mice, with no effect in control animals. Spectral analysis was used to monitor autonomic cardiovascular function. The circadian rhythm observed in systolic arterial pressure variance and its low-frequency component in control mice was absent in db/db mice. There were no changes in HR variability and spontaneous baroreflex sensitivity between control and db/db mice. The results document an age-related increase in MAP in db/db mice, which can be reduced by antagonism of angiotensin II AT(1) receptors, and alterations in autonomic balance and components of the renin-angiotensin system.
Senador
Danielle
D
Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
Kanakamedala
Keerthy
K
Irigoyen
Maria Claudia
MC
Morris
Mariana
M
Elased
Khalid M
KM
D000375:Aging / Q000235:genetics / Q000502:physiology; D000804:Angiotensin II / Q000097:blood; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D017704:Baroreflex / Q000235:genetics / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002319:Cardiovascular System / Q000187:drug effects / Q000503:physiopathology*; D002940:Circadian Rhythm / Q000235:genetics / Q000502:physiology; D048909:Diabetes Complications / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology*; D004195:Disease Models, Animal; D006339:Heart Rate / Q000502:physiology; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D009043:Motor Activity / Q000502:physiology; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D010641:Phenotype; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology; D054411:Receptors, Leptin / Q000235:genetics*
D047228:Angiotensin II Type 1 Receptor Blockers; D044140:Receptor, Angiotensin, Type 1; D054411:Receptors, Leptin; C515447:leptin receptor, mouse; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A; D019808:Losartan